Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine safety and effectiveness of transplanting lungs
from Hepatitis C-positive donors into Hepatitis C-negative patients on the lung transplant
waitlist, who will then be treated with appropriate direct-acting antiviral (DAA) after
transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Elbasvir-grazoprevir drug combination Sofosbuvir-velpatasvir drug combination